{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:03Z","timestamp":1791256743798,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005036","name":"Universitetet i Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2712-4","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T09:20:40Z","timestamp":1471598440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models"],"prefix":"10.1186","volume":"16","author":[{"given":"I. A.","family":"Netland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. E.","family":"F\u00f8rde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Leiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. S.","family":"Skeie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Gjerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. \u00d8.","family":"Enger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Goplen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,19]]},"reference":[{"issue":"5","key":"2712_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366.","journal-title":"Lancet Oncol"},{"key":"2712_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/2152-7806.137196","volume":"5","author":"TA Wilson","year":"2014","unstructured":"Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int. 2014;5:64.","journal-title":"Surg Neurol Int"},{"key":"2712_CR3","doi-asserted-by":"crossref","unstructured":"Nature Biotechnology. Signal transduction as a drug-discovery platform. Nat Biotechnol. 2000;18:IT37-9.","DOI":"10.1038\/80076"},{"issue":"4","key":"2712_CR4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.mam.2010.04.001","volume":"31","author":"A Levitzki","year":"2010","unstructured":"Levitzki A, Klein S. Signal transduction therapy of cancer. Mol Aspects Med. 2010;31(4):287\u2013329.","journal-title":"Mol Aspects Med"},{"issue":"1-3","key":"2712_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejphar.2009.10.009","volume":"625","author":"T Christoffersen","year":"2009","unstructured":"Christoffersen T, et al. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Eur J Pharmacol. 2009;625(1-3):6\u201322.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2712_CR6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1634\/theoncologist.12-12-1443","volume":"12","author":"C Widakowich","year":"2007","unstructured":"Widakowich C, et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12(12):1443\u201355.","journal-title":"Oncologist"},{"issue":"2","key":"2712_CR7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u201377.","journal-title":"Cell"},{"issue":"3","key":"2712_CR8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10014-013-0174-9","volume":"31","author":"M Nakada","year":"2014","unstructured":"Nakada M, et al. Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma. Brain Tumor Pathol. 2014;31(3):198\u2013207.","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"2712_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cncr.22741","volume":"110","author":"S Sathornsumetee","year":"2007","unstructured":"Sathornsumetee S, et al. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110(1):13\u201324.","journal-title":"Cancer"},{"issue":"3","key":"2712_CR10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archneurol.2010.5","volume":"67","author":"J Clarke","year":"2010","unstructured":"Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67(3):279\u201383.","journal-title":"Arch Neurol"},{"issue":"3","key":"2712_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"J Rodon","year":"2013","unstructured":"Rodon J, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143\u201353.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2712_CR12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"SM Maira","year":"2008","unstructured":"Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7(7):1851\u201363.","journal-title":"Mol Cancer Ther"},{"key":"2712_CR13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/1471-2407-9-465","volume":"9","author":"J Wang","year":"2009","unstructured":"Wang J, et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer. 2009;9:465.","journal-title":"BMC Cancer"},{"issue":"3","key":"2712_CR14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3171\/jns.1990.72.3.0463","volume":"72","author":"R Bjerkvig","year":"1990","unstructured":"Bjerkvig R, et al. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990;72(3):463\u201375.","journal-title":"J Neurosurg"},{"issue":"8","key":"2712_CR15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.bjc.6604995","volume":"100","author":"P Cao","year":"2009","unstructured":"Cao P, et al. Activity of a novel, dual PI3-kinase\/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer. 2009;100(8):1267\u201376.","journal-title":"Br J Cancer"},{"issue":"8","key":"2712_CR16","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","volume":"8","author":"TJ Liu","year":"2009","unstructured":"Liu TJ, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009;8(8):2204\u201310.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2712_CR17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/nos117","volume":"14","author":"PY Wen","year":"2012","unstructured":"Wen PY, et al. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012;14(7):819\u201329.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2712_CR18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20070003","volume":"404","author":"C Chaussade","year":"2007","unstructured":"Chaussade C, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007;404(3):449\u201358.","journal-title":"Biochem J"},{"issue":"10","key":"2712_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.tem.2010.06.005","volume":"21","author":"Z Cheng","year":"2010","unstructured":"Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab. 2010;21(10):589\u201398.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2712_CR20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11060-015-1815-0","volume":"124","author":"MT Tieu","year":"2015","unstructured":"Tieu MT, et al. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol. 2015;124(1):119\u201326.","journal-title":"J Neurooncol"},{"issue":"3","key":"2712_CR21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","volume":"245","author":"J Ozer","year":"2008","unstructured":"Ozer J, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194\u2013205.","journal-title":"Toxicology"},{"issue":"7","key":"2712_CR22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/oxfordjournals.aje.a009315","volume":"146","author":"AA Meltzer","year":"1997","unstructured":"Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol. 1997;146(7):565\u201371.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2712_CR23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10637-015-0218-6","volume":"33","author":"JC Bendell","year":"2015","unstructured":"Bendell JC, et al. A phase 1 study of the sachet formulation of the oral dual PI3K\/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs. 2015;33(2):463\u201371.","journal-title":"Invest New Drugs"},{"key":"2712_CR24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2013.00108","volume":"3","author":"M Martini","year":"2013","unstructured":"Martini M, et al. Targeting PI3K in Cancer: Any Good News? Front Oncol. 2013;3:108.","journal-title":"Front Oncol"},{"issue":"4","key":"2712_CR25","doi-asserted-by":"crossref","first-page":"e60537","DOI":"10.1371\/journal.pone.0060537","volume":"8","author":"CC Horn","year":"2013","unstructured":"Horn CC, et al. Why can\u2019t rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS One. 2013;8(4):e60537.","journal-title":"PLoS One"},{"issue":"21","key":"2712_CR26","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1111\/febs.12428","volume":"280","author":"GC Smith","year":"2013","unstructured":"Smith GC, et al. Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. FEBS J. 2013;280(21):5337\u201349.","journal-title":"FEBS J"},{"issue":"5","key":"2712_CR27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1078-0432.CCR-13-1607","volume":"20","author":"CR Alcazar Gil del","year":"2014","unstructured":"Gil del Alcazar CR, et al. Inhibition of DNA double-strand break repair by the dual PI3K\/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res. 2014;20(5):1235\u201348.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2712_CR28","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/0008-5472.CAN-14-3122","volume":"75","author":"S Klingler","year":"2015","unstructured":"Klingler S, et al. Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. Cancer Res. 2015;75(10):2109\u201319.","journal-title":"Cancer Res"},{"issue":"1","key":"2712_CR29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.canlet.2015.07.007","volume":"367","author":"Z Yu","year":"2015","unstructured":"Yu Z, et al. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 2015;367(1):58\u201368.","journal-title":"Cancer Lett"},{"issue":"3","key":"2712_CR30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/bjc.2014.628","volume":"112","author":"J Cebulla","year":"2015","unstructured":"Cebulla J, et al. MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. Br J Cancer. 2015;112(3):504\u201313.","journal-title":"Br J Cancer"},{"issue":"2","key":"2712_CR31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.canlet.2014.12.015","volume":"357","author":"YH Chen","year":"2015","unstructured":"Chen YH, et al. Dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357(2):582\u201390.","journal-title":"Cancer Lett"},{"issue":"3","key":"2712_CR32","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1124\/mol.115.099143","volume":"88","author":"DE Durrant","year":"2015","unstructured":"Durrant DE, et al. Targeted inhibition of phosphoinositide 3-kinase\/mammalian target of rapamycin sensitizes pancreatic cancer cells to doxorubicin without exacerbating cardiac toxicity. Mol Pharmacol. 2015;88(3):512\u201323.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"2712_CR33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s13277-014-2667-5","volume":"36","author":"J E","year":"2015","unstructured":"E J, et al. Combine MEK inhibition with PI3K\/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. Tumour Biol. 2015;36(2):1091\u20137.","journal-title":"Tumour Biol"},{"issue":"1","key":"2712_CR34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2015.04.028","volume":"138","author":"S Schrauwen","year":"2015","unstructured":"Schrauwen S, et al. Dual blockade of PI3K\/AKT\/mTOR (NVP-BEZ235) and Ras\/Raf\/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Gynecol Oncol. 2015;138(1):165\u201373.","journal-title":"Gynecol Oncol"},{"issue":"31","key":"2712_CR35","doi-asserted-by":"crossref","first-page":"32039","DOI":"10.18632\/oncotarget.5055","volume":"6","author":"N Sharma","year":"2015","unstructured":"Sharma N, et al. PI3K\/AKT\/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget. 2015;6(31):32039\u201360.","journal-title":"Oncotarget"},{"issue":"21","key":"2712_CR36","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.18632\/oncotarget.2260","volume":"5","author":"J Wong","year":"2014","unstructured":"Wong J, et al. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia. Oncotarget. 2014;5(21):10460\u201372.","journal-title":"Oncotarget"},{"issue":"1","key":"2712_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3\u201314.","journal-title":"NeuroRx"},{"issue":"2","key":"2712_CR38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-13-0655","volume":"13","author":"Y Wang","year":"2014","unstructured":"Wang Y, et al. Activation of AR sensitizes breast carcinomas to NVP-BEZ235\u2032s therapeutic effect mediated by PTEN and KLLN upregulation. Mol Cancer Ther. 2014;13(2):517\u201327.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2712_CR39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s13277-014-2709-z","volume":"36","author":"X Yu","year":"2015","unstructured":"Yu X, et al. Androgen receptor signaling regulates growth of glioblastoma multiforme in men. Tumour Biol. 2015;36(2):967\u201372.","journal-title":"Tumour Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2712-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T15:58:15Z","timestamp":1568303895000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2712-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,19]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2712-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,19]]},"article-number":"657"}}